Please login to the form below
Yescarta
This page shows the latest Yescarta news and features for those working in and with pharma, biotech and healthcare.
BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
Kite has already seen success with its own CAR T treatments, which includes Tecartus (brexucabtagene autoleucel) and Yescarta (axicabtagene ciloleucel). ... Meanwhile, Yescarta is used to treat follicular lymphoma and is also approved in the US for the
Latest news
-
Kite’s CAR-T therapy Yescarta shows positive results in second-line lymphoma study
After a median follow-up of two years, Yescarta showed a 60.2% improvement in event-free survival (EFS) compared to SOC. ... Yescarta has been instrumental in transforming outcomes for patients with third-line LBCL.
-
Gilead’s Q1 revenues lifted by COVID-19 med Veklury as HIV drugs take a hit
Gilead was also bolstered by sales of its cell therapy products, which jumped by 36% to $191m in the first quarter, with Yescarta bringing in $160m and Tecartus bringing in $31m.
-
Yescarta gains first FDA approval for indolent follicular lymphoma
marginal zone lymphoma patients were enrolled and treated with Yescarta following two or more prior lines of therapy. ... Kite also recently revealed some positive data for Yescarta in the first-line setting for patients with high-risk large B-cell
-
FDA approves BMS’ blood cancer CAR T therapy after delay
Gilead/Kite’s Yescarta (axicabtagene ciloleucel) was the first FDA-approved CAR T therapy for the treatment of adult patients with relapsed or refractory LBCL, including DLBCL.
-
Gilead’s COVID-19 drug Veklury brought in almost $2bn in Q4
This includes Yescarta (axicabtagene ciloleucel) and Tecartus M (brexucabtagene autoleucel), which helped to grow sales by 34% to $163m in Q4 and 33% to $607m for the entire year. ... Gilead said growth in this area was caused primarily by continued
Kite’s CAR-T therapy Yescarta shows positive results in second-line lymphoma study
Gilead’s Q1 revenues lifted by COVID-19 med Veklury as HIV drugs take a hit
Yescarta gains first FDA approval for indolent follicular lymphoma
FDA approves BMS’ blood cancer CAR T therapy after delay
Gilead’s COVID-19 drug Veklury brought in almost $2bn in Q4
More from news
Approximately 14 fully matching, plus 57 partially matching documents found.
Latest Intelligence
-
Keeping up with the developing regulatory requirements for gene and cell therapies
By Clive Glover. Since the approval of the first five gene or gene-modified cell therapies in the US – Luxturna, Yescarta, Tecartus, Kymriah and Zolgensma – this new technology has been evolving
-
Cortellis Drugs to Watch in 2020 report
as Kymriah and Yescarta.
-
25 Women Leaders in UK Healthcare (part 2)
It has brought to market not one but two groundbreaking drugs in hepatitis C, Harvoni, and in diffuse large B cell lymphoma, Yescarta, one of the first CAR-T therapies to
-
Bluebird: on a mission to ‘recode’ the DNA of healthcare
years. Kymriah’s US list price is $475, 000 while Gilead’s rival drug, Yescarta, is priced at $373, 000 (with European prices substantially lower than this).
-
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
can make it on to the market early – agreements on the two CAR-T drugs, Novartis’ Kymriah and Gilead’s Yescarta providing an encouraging sign.
Keeping up with the developing regulatory requirements for gene and cell therapies
Cortellis Drugs to Watch in 2020 report
25 Women Leaders in UK Healthcare (part 2)
Bluebird: on a mission to ‘recode’ the DNA of healthcare
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.
Latest from PMHub
-
Training the next generation of biotech leaders
In August, Novartis’ revolutionary CAR-T therapy, Kymriah, was approved. This was quickly followed by the approval of Kite’s Yescarta in October.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
-
Events Executive
-
Depending on Experience
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
-
Digital account director
-
Competitive
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’
- Lilly and Kumquat Biosciences link up in $2bn-plus immuno-oncology deal
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- BMS’ Q2 results beat expectations with strong performance across core therapy areas
- Amanda Pritchard becomes NHS England’s first female chief executive
- Understanding the ‘real world’ starts and ends with the patient
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- Roche engaged in talks with FDA for Alzheimer’s drug candidate
- Pharma’s authentic proof of purpose influences decisions among HCPs and payers
- Merck & Co's cancer drug Keytruda gaining traction in US
- Tyson Fury takes on his Invisible Opponent in hard hitting ad for suicide prevention charity Campaign Against Living Miserably
PMHub
EPG Health
REACH, ENGAGE & MEASURE HCPs ONLINE - Accomplish meaningful engagement via Medthority (www.medthority.com), a trusted independent medical website. Support the...
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
